Beijing, Sept 4, 2026 — China’s National Drug Centralized Procurement Office approved the 13th batch of information changes for selected drugs under the national volume-based procurement program, allowing winning manufacturers to update marketing authorization holders, production sites, specifications, packaging, and corporate names without losing their selected status.
Policy Snapshot
| Attribute | Detail |
|---|---|
| Issuer | National Drug Centralized Procurement Joint Office |
| Document | Notice on Information Changes of Selected Drugs in National Centralized Procurement (13th Batch) |
| Effective date | Sept 4, 2026 |
| Scope | Selected drugs under national volume-based procurement |
| Permitted changes | Marketing authorization holder; manufacturer; specifications; packaging; corporate name |
| Condition | Selected enterprises must meet specified eligibility criteria |
| Action required | Information linkage updates; platform listing adjustments; procurement coordination |
Key Provisions
Under the National Drug Centralized Procurement Document and related regulations, winning enterprises that satisfy defined conditions may modify critical product and corporate information while retaining their selected procurement qualification. The office verified enterprise application materials before granting approval for the 13th batch of changes. All relevant parties—including medical institutions, distributors, and procurement platforms—must promptly complete information synchronization, online listing updates, and purchasing workflow adjustments to reflect the revised drug details.
Market Impact Analysis
The 13th batch approval signals continued regulatory flexibility within China’s rigid national procurement framework, acknowledging that corporate restructuring, manufacturing consolidation, and product line optimization are inevitable in a market undergoing rapid consolidation. By allowing marketing authorization holder and production site transfers without stripping selected status, regulators are preventing supply disruptions that could arise if every corporate change triggered automatic re-tendering.
For pharmaceutical companies, the change mechanism provides a critical pathway to optimize manufacturing footprints and transfer assets between subsidiaries without sacrificing the hard-won volume commitments secured through national bidding. However, the requirement to meet unspecified “certain conditions” implies that not all change requests are automatically approved, creating a compliance gate that favors well-resourced enterprises capable of navigating administrative verification.
For hospitals and procurement platforms, the batch release demands immediate system updates to ensure that purchasing records, invoice matching, and inventory management align with the revised drug information. Failure to synchronize could result in settlement delays or compliance flags during audits.
Forward-Looking Statement
Industry analysts expect the national procurement office to maintain a regular cadence of information change approvals—likely quarterly or monthly—as the volume-based procurement program matures and corporate restructuring accelerates across the domestic pharmaceutical sector. The 13th batch suggests the approval pipeline is processing applications efficiently, with minimal backlog. Companies planning mergers, acquisitions, or manufacturing transfers for selected products should file change applications proactively, as the office’s willingness to approve such modifications reduces the regulatory risk traditionally associated with post-award corporate actions. The batch release also sets a template for provincial procurement alliances, many of which are expected to adopt similar change-management protocols to ensure supply continuity across decentralized procurement networks.-China Health Reform Pulse
Policy Source: https://www.smpaa.cn/gjsdcg/2026/09/04/24314.shtml